Expression of a Gi-coupled receptor in the heart causes impaired Ca2+ handling, myofilament injury, and dilated cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 1, 2008, Pages

  McCloskey, Diana T ^a   Turcato, Sally ^a   Wang, Guan Ying ^a   Turnbull, Lynne ^a   Zhu, Bo Qing ^a   Bambino, Thomas ^a   Nguyen, Anita P ^a   Lovett, David H ^a   Nissenson, Robert A ^a   Karliner, Joel S ^a   Baker, Anthony J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

opioid receptor; Conditional expression; Contraction; Matrix metalloproteinase 2; Sarco(endo)plasmic reticulum Ca 2+ ATPase

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CALCIUM; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GELATINASE A; SPIRADOLINE; DRUG DERIVATIVE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; MMP2 PROTEIN, MOUSE; NALTREXONE; NARCOTIC ANTAGONIST; NORBINALTORPHIMINE; PYRROLIDINE DERIVATIVE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE INJURY; HEART PERFUSION; HEMODYNAMICS; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; MICROFILAMENT; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TRANSGENIC MOUSE; ULTRASTRUCTURE;

ANIMALS; CALCIUM; CARDIOMYOPATHY, DILATED; CYCLIC AMP; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; MATRIX METALLOPROTEINASE 2; MICE; MICE, TRANSGENIC; MICROFILAMENTS; MYOCARDIAL CONTRACTION; MYOCARDIUM; NALTREXONE; NARCOTIC ANTAGONISTS; PYRROLIDINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID, KAPPA; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 38149108119     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00829.2007     Document Type: Article

References (47)

1. Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33: 648-656, 2003.
2. Backx PH, Ter Keurs HE. Fluorescent properties of rat cardiac trabeculae microinjected with fura 2 salt. Am J Physiol Heart Circ Physiol 264: H1098-H1110, 1993.
3. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292: H1847-H1860, 2007.
4. Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E. Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249-1265, 1990.
5. Cotte N, Fong J, Kwa A, Redfern C, Franklin A, Conklin BR, Nanevicz T. Prevention and rescue of a mouse model of dilated cardiomyopathy targeting the hyperactive signaling of a Gi-coupled receptor (Abstract). Circulation 104, Suppl 17, II367, 2001.
6. Coward P, Wada HG, Falk MS, Chan SD, Meng F, Akil H, Conklin BR. Controlling signaling with a specifically designed Gi-coupled receptor. Proc Natl Acad Sci USA 95: 352-357, 1998.
7. Daniels MC, Naya T, Rundell VL, de Tombe PP. Development of contractile dysfunction in rat heart failure: hierarchy of cellular events. Am J Physiol Regul Integr Comp Physiol 293: R284-R292, 2007.
8. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 82: 189-197, 1988.
9. Feldman AM, Jackson DG, Bristow MR, Cates AE, Van Dop C. Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate. J Mol Cell Cardiol 23: 439-452, 1991.
10. 2+-ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med 74: 321-332, 1996.
11. Fu LX, Liang QM, Waagstein F, Hoebeke J, Sylvén C, Jansson E, Sotonyi P, Hjalmarson A. Increase in functional activity rather than in amount of Giα in failing human heart with dilated cardiomyopathy. Cardiovasc Res 26: 950-955, 1992.
12. Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, Hoebeke J. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91: 1964-1968, 1993.
13. Furth PA, St Onge L, Boger H, Gruss P, Gossen M, Kistner A, Bujard H, Hennighausen L. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 91: 9302-9306, 1994.
14. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 34: 951-969, 2002.
15. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 75: 434-442, 1994.
16. Houser SR, Piacentino V 3rd, Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32: 1595-1607, 2000.
17. Ishizaka S, Sievers RE, Zhu BQ, Rodrigo MC, Joho S, Foster E, Simpson PC, Grossman W. New technique for measurement of left ventricular pressure in conscious mice. Am J Physiol Heart Circ Physiol 286: H1208-H1215, 2004.
18. Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA. Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269: 21505-21511, 1994.
19. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation 96: 3416-3422, 1997.
20. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 31: 625-632, 1996.
21. Matsui S, Fu ML, Shimizu M, Fukuoka T, Teraoka K, Takekoshi N, Murakami E, Hjalmarson A. Dilated cardiomyopathy defines serum autoantibodies against G-protein-coupled cardiovascular receptors. Autoimmunity 21: 85-88, 1995.
22. 1A/C-knockout and wild type mice. J Mol Cell Cardiol 34: 1007-1017, 2002.
23. 1B-adrenoceptor double-knockout mice. J Mol Cell Cardiol 35: 1207-1216, 2003.
24. McCloskey DT, Turnbull L, Swigart PM, Zambon AC, Turcato S, Joho S, Grossman W, Conklin BR, Simpson PC, Baker AJ. Cardiac transgenesis with the tetracycline transactivator changes myocardial function and gene expression. Physiol Genomics 22: 118-126, 2005.
25. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92: 778-784, 1995.
26. 2+- transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 90: 653-657, 1994.
27. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Doring V, Kalmar P. Increase in myocardial Gi-proteins in heart failure. Lancet 2: 936-937, 1988.
28. Nissenson RA, Strewler GJ, Williams RD, Leung SC. Activation of the parathyroid hormone receptor-adenylate cyclase system in osteosarcoma cells by a human renal carcinoma factor. Cancer Res 45: 5358-5363, 1985.
29. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46: 307-315, 2000.
30. 2+ signaling in neonatal rat cardiac myocytes. Am J Physiol Cell Physiol 292: C2269-C2275, 2007.
31. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, Conklin BR. Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice. Nat Biotechnol 17: 165-169, 1999.
32. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR. Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc Natl Acad Sci USA 97: 4826-4831, 2000.
33. Sakata Y, Yamamoto K, Mano T, Nishikawa N, Yoshida J, Hori M, Miwa T, Masuyama T. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109: 2143-2149, 2004.
34. Schillinger W, Meyer M, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Unaltered ryanodine receptor protein levels in ischemic cardiomyopathy. Mol Cell Biochem 160-161: 297-302, 1996.
35. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 92: 3220-3228, 1995.
36. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 31: 479-491, 1999.
37. Sen L, Cui G, Fonarow GC, Laks H. Differences in mechanisms of SR dysfunction in ischemic vs. idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 279: H709-H718, 2000.
38. Shan D, Wang H, Su Y, Jing Y, Wong TM. κ-Opioid receptor stimulation inhibits cardiac hypertrophy induced by 1-adrenoceptor stimulation in the rat. Eur J Pharmacol 555: 100-105, 2007.
39. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944-1949, 2000.
40. 2+ exchanger in end-stage human heart failure. Circ Res 75: 443-453, 1994.
41. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 74: 56-63, 2007.
42. 1D-AR. Am J Physiol Heart Circ Physiol 284: H1104-H1109, 2003.
43. Wang G, Wang H, Yang Y, Wong TM. κ-Opioid receptor stimulation inhibits growth of neonatal rat ventricular myocytes. Eur J Pharmacol 498: 53-58, 2004.
44. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69: 688-696, 2006.
45. Wu WT, Chen CN, Lin CI, Chen JH, Lee H. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology 146: 3387-3400, 2005.
46. Yu XC, Li HY, Wang HX, Wong TM. U50,488H inhibits effects of norepinephrine in rat cardiomyocytes-cross-talk between κ-opioid and β-adrenergic receptors. J Mol Cell Cardiol 30: 405-413, 1998.
47. Yu Z, Redfern CS, Fishman GI. Conditional transgene expression in the heart. Circ Res 79: 691-697, 1996.